NDRA · Insider Trading
ENDRA Life Sciences Inc. Common Stock
Every open-market purchase and sale reported by NDRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | Richard Jacroux | Chief Financial Officer | A | +13,461 | — |
| 2026-03-04 | Alexander Y Tokman | Chief Executive Officer | A | +26,921 | — |
| 2026-01-23 | Richard Jacroux | Chief Financial Officer | A | +20,000 | — |
| 2026-01-23 | Anthony Digiandomenico | Director | A | +60,324 | — |
| 2026-01-23 | Alexander Y Tokman | Chief Executive Officer | A | +75,000 | — |
| 2026-01-23 | Lou Basenese | Director | A | +60,324 | — |
| 2026-01-23 | Michael Harsh | Director | A | +60,324 | — |
| 2025-10-15 | Anthony Digiandomenico | Director | A | +70,822 | +$500.00K |
| 2025-07-01 | Anthony Digiandomenico | Director | A | +5,384 | — |
| 2025-07-01 | Michael Harsh | Director | A | +5,384 | — |
| 2025-07-01 | Lou Basenese | Director | A | +5,384 | — |
| 2024-09-05 | UBS Group AG | — | Buy | — | — |
| 2024-08-29 | UBS Group AG | 10%+ Owner | Buy | +3,715 | +$2.05K |
| 2024-02-23 | Michael Harsh | Director | A | +600 deriv. | — |
| 2024-02-23 | Anthony Digiandomenico | Director | A | +600 deriv. | — |
| 2024-02-23 | Alexander Y Tokman | Director | A | +600 deriv. | — |
| 2024-02-23 | Lou Basenese | Director | A | +600 deriv. | — |
| 2023-05-22 | Michael Milos Thornton | Chief Technology Officer | Buy | +15,000 | +$24.75K |
| 2023-05-03 | Anthony Digiandomenico | Director | Buy | +83,333 | +$100.00K |
| 2023-02-01 | Lou Basenese | Director | A | +6,746 deriv. | — |
| 2023-02-01 | Francois Roger Michelon | Chief Executive Officer | A | +69,531 deriv. | — |
| 2023-02-01 | Irina Pestrikova | Senior Director, Finance | A | +8,000 deriv. | — |
| 2023-02-01 | Anthony Digiandomenico | Director | A | +9,621 deriv. | — |
| 2023-02-01 | Michael Milos Thornton | Chief Technology Officer | A | +68,066 deriv. | — |
| 2023-02-01 | Michael Harsh | Director | A | +9,634 deriv. | — |
| 2023-02-01 | Alexander Y Tokman | Director | A | +9,621 deriv. | — |
| 2022-12-13 | Michael Milos Thornton | Chief Technology Officer | Buy | +1,500 | +$5.10K |
| 2022-11-28 | Alexander Y Tokman | Director | Buy | +10,000 | +$1.70K |
| 2022-08-24 | Alexander Y Tokman | Director | Buy | +20,000 | +$5.20K |
| 2022-08-24 | Michael Milos Thornton | Chief Technology Officer | Buy | +20,000 | +$5.40K |
| 2022-05-31 | Michael Milos Thornton | Chief Technology Officer | Buy | +25,000 | +$5.25K |
| 2022-05-23 | Michael Milos Thornton | Chief Technology Officer | Buy | +25,000 | +$5.50K |
| 2022-05-19 | Francois Roger Michelon | Chief Executive Officer | Buy | +5,100 | +$969 |
| 2022-05-17 | Alexander Y Tokman | Director | Buy | +100,000 | +$19.63K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Anthony Digiandomenico | Director | 136,589 | $652.90K |
| Alexander Y Tokman | Chief Executive Officer | 101,926 | $487.21K |
| Michael Harsh | Director | 65,710 | $314.09K |
| Lou Basenese | Director | 65,709 | $314.09K |
| Richard Jacroux | Chief Financial Officer | 33,461 | $159.94K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NDRA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.